Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Agios Pharmaceuticals, Inc.

AGIO

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Last trade $29.75
Day change -$0.40 (-1.33%)
Day range $28.95 – $31.26
Volume 304,110
Market cap $1.80B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.8B
Price / earnings
—
Price / book
1.84×
Price / sales
12.8×
EV / sales
11.89×
EV / EBITDA
-4.05×

Profitability

Earnings per share
-$6.23
Return on assets
-35.05%
Return on equity
-38.08%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.69×
Quick ratio
9.21×
Cash ratio
1.66×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$335.97M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AGIO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$55.39M$44.75M$20.75M$19.97M$12.88M$12.46M$8.73M$10.73M
Cost of revenue$2.53M$3M$1.32M$1.88M$1.68M$1.7M$1.09M$1.26M
Gross profit$52.86M$41.75M$19.43M$18.09M$11.2M$10.75M$7.64M$9.47M
Selling, general and administrative$56.53M$51.55M$48.3M$51.61M$41.27M$45.87M$41.53M$51.7M
Research and development$73.49M$100.75M$81.15M$88.06M$86.8M$91.94M$72.74M$82.81M
Total operating expenses$130.02M$152.3M$129.45M$139.67M$128.07M$137.81M$114.27M$134.51M
Operating income-$77.16M-$110.55M-$110.03M-$121.58M-$116.87M-$127.06M-$106.63M-$125.04M
Interest expense$8.88M$9.73M$10.8M$0$13.37M$14.51M$16.09M$0
Income before taxes-$65.05M-$100.7M-$99.11M-$109.06M-$103.43M-$112.02M-$89.29M-$105.4M
Income taxes$0$0$0-$1.02M$0$0$0-$8.88M
Net income-$65.05M-$100.7M-$99.11M-$108.04M-$103.43M-$112.02M-$89.29M-$96.52M
Net income attributable to common shareholders-$65.05M-$100.7M-$99.11M-$108.04M-$103.43M-$112.02M-$89.29M-$96.52M
EBITDA-$75.71M-$109.2M-$108.66M-$120.31M-$115.5M-$125.8M-$105.35M-$123.67M
Basic earnings per share-$1.09-$1.69-$1.69-$1.85-$1.78-$1.93-$1.55-$1.69
Diluted earnings per share-$1.09-$1.69-$1.69-$1.85-$1.78-$1.93-$1.55-$1.61

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.

Zacks Investment Research

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

IDEAYA Biosciences reported a Q3 loss of $1.22 per share, beating the consensus estimate of $1.26 loss by 3.18%. The company posted revenues of $10.24 million, surpassing consensus by 14.69%, though this represents a significant decline from $207.83 million in the year-ago quarter. The stock has underperformed the S&P 500 by 18.7% year-to-date and carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line

Danaher Corporation reported Q3 adjusted EPS of $2.11, beating estimates by 9.9%, with revenues of $6.55 billion in line with expectations. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62 and expects 2.5% core revenue growth. Diagnostics segment sales jumped 17% driven by acquisitions, though respiratory testing revenues declined significantly from $500M to $350M year-over-year.

Zacks Investment Research

Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?

Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy).

The Motley Fool

4 High-Risk Stocks Built for Big Returns

The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.